MUC16 Contributes to the Metastasis of Pancreatic Ductal Adenocarcinoma Through Focal Adhesion Mediated Signaling Mechanism

Overview

Journal Genes Cancer

Specialty Oncology

Date 2016 Jul 7

PMID 27382435

Citations 53

Authors

Sakthivel Muniyan

Dhanya Haridas

Seema Chugh

Satyanarayana Rachagani

Imayavaramban Lakshmanan

Suprit Gupta

Parthasarathy Seshacharyulu

Lynette M Smith

Moorthy P Ponnusamy

Surinder K Batra

Affiliations

Soon will be listed here.

Abstract

MUC16, a heavily glycosylated type-I transmembrane mucin is overexpressed in several cancers including pancreatic ductal adenocarcinoma (PDAC). Previously, we have shown that MUC16 is significantly overexpressed in human PDAC tissues. However, the functional consequences and its role in PDAC is poorly understood. Here, we show that MUC16 knockdown decreases PDAC cell proliferation, colony formation and migration in vitro. Also, MUC16 knockdown decreases the tumor formation and metastasis in orthotopic xenograft mouse model. Mechanistically, immunoprecipitation and immunofluorescence analyses confirms MUC16 interaction with galectin-3 and mesothelin in PDAC cells. Adhesion assay displayed decreased cell attachment of MUC16 knockdown cells with recombinant galectin-1 and galectin-3 protein. Further, CRISPR/Cas9-mediated MUC16 knockout cells show decreased tumor-associated carbohydrate antigens (T and Tn) in PDAC cells. Importantly, carbohydrate antigens were decreased in the region that corresponds to MUC16 and suggests for the decreased MUC16-galectin interactions. Co-immunoprecipitation also revealed a novel interaction between MUC16 and FAK in PDAC cells. Interestingly, we observed decreased expression of mesenchymal and increased expression of epithelial markers in MUC16-silenced cells. Additionally, MUC16 loss showed a decreased FAK-mediated Akt and ERK/MAPK activation. Altogether, these findings suggest that MUC16-focal adhesion signaling may play a critical role in facilitating PDAC growth and metastasis.

Citing Articles

Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization.

Ewa T, Panchwagh N, Tai C, Avula L, Joseph S, Rudloff M FASEB J. 2024; 38(24):e70247.

PMID: 39673668 PMC: 11646052. DOI: 10.1096/fj.202400446R.

An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum.

Devasahayam Arokia Balaya R, Sen P, Grant C, Zenka R, Sappani M, Lakshmanan J J Gastroenterol. 2024; .

PMID: 39666045 DOI: 10.1007/s00535-024-02197-6.

Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6.

Aguilar E, Sagar S, Murray B, Rajesh C, Lei E, Michaud S Mol Cancer Ther. 2024; 23(6):836-853.

PMID: 38394685 PMC: 11660185. DOI: 10.1158/1535-7163.MCT-23-0868.

MUC1 and MUC16: critical for immune modulation in cancer therapeutics.

Chen X, Sandrine I, Yang M, Tu J, Yuan X Front Immunol. 2024; 15:1356913.

PMID: 38361923 PMC: 10867145. DOI: 10.3389/fimmu.2024.1356913.

Proteomic profiling identifies biomarkers of COVID-19 severity.

Harriott N, Ryan A Heliyon. 2024; 10(1):e23320.

PMID: 38163173 PMC: 10755324. DOI: 10.1016/j.heliyon.2023.e23320.

References

Partridge E, Le Roy C, Di Guglielmo G, Pawling J, Cheung P, Granovsky M . Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 2004; 306(5693):120-4. DOI: 10.1126/science.1102109. View

Saxena M, Singh S, Negi M, Srivastava A, Trivedi R, Singh U . Expression profiling of G2/M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients. J Cancer Res Ther. 2010; 6(2):167-71. DOI: 10.4103/0973-1482.65242. View

Chauhan S, Singh A, Ruiz F, Johansson S, Jain M, Smith L . Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol. 2006; 19(10):1386-94. DOI: 10.1038/modpathol.3800646. View

Hauselmann I, Borsig L . Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 2014; 4:28. PMC: 3923139. DOI: 10.3389/fonc.2014.00028. View

Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom V, Standop J . Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008; 98(9):1540-7. PMC: 2391106. DOI: 10.1038/sj.bjc.6604329. View

Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M . Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 2012; 103(4):739-46. PMC: 7659350. DOI: 10.1111/j.1349-7006.2012.02214.x. View

Gubbels J, Felder M, Horibata S, Belisle J, Kapur A, Holden H . MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010; 9:11. PMC: 2818693. DOI: 10.1186/1476-4598-9-11. View

Langley R, Fidler I . Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 2007; 28(3):297-321. DOI: 10.1210/er.2006-0027. View

Chen S, Dallas M, Balzer E, Konstantopoulos K . Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J. 2011; 26(3):1349-59. PMC: 3289508. DOI: 10.1096/fj.11-195669. View

10.

Streppel M, Vincent A, Mukherjee R, Campbell N, Chen S, Konstantopoulos K . Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012; 43(10):1755-63. PMC: 3547617. DOI: 10.1016/j.humpath.2012.01.005. View

11.

Di Lella S, Sundblad V, Cerliani J, Guardia C, Estrin D, Vasta G . When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry. 2011; 50(37):7842-57. PMC: 3429939. DOI: 10.1021/bi201121m. View

12.

Chakraborty S, Swanson B, Bonthu N, Batra S . Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases. J Clin Pathol. 2010; 63(7):579-84. PMC: 2920126. DOI: 10.1136/jcp.2010.076125. View

13.

Chaturvedi P, Singh A, Moniaux N, Senapati S, Chakraborty S, Meza J . MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res. 2007; 5(4):309-20. DOI: 10.1158/1541-7786.MCR-06-0353. View

14.

Senapati S, Chaturvedi P, Chaney W, Chakraborty S, Gnanapragassam V, Sasson A . Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin Cancer Res. 2010; 17(2):267-74. PMC: 3023008. DOI: 10.1158/1078-0432.CCR-10-1937. View

15.

Das S, Rachagani S, Torres-Gonzalez M, Lakshmanan I, Majhi P, Smith L . Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget. 2015; 6(8):5772-87. PMC: 4467401. DOI: 10.18632/oncotarget.3308. View

16.

Bast Jr R, Klug T, St John E, Jenison E, Niloff J, Lazarus H . A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309(15):883-7. DOI: 10.1056/NEJM198310133091503. View

17.

Gubbels J, Belisle J, Onda M, Rancourt C, Migneault M, Ho M . Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5(1):50. PMC: 1635730. DOI: 10.1186/1476-4598-5-50. View

18.

Mylonas I, Makovitzky J, Richter D, Jeschke U, Briese V, Friese K . Immunohistochemical expression of the tumour marker CA-125 in normal, hyperplastic and malignant endometrial tissue. Anticancer Res. 2003; 23(2A):1075-80. View

19.

Chugh S, Gnanapragassam V, Jain M, Rachagani S, Ponnusamy M, Batra S . Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets. Biochim Biophys Acta. 2015; 1856(2):211-25. PMC: 4663118. DOI: 10.1016/j.bbcan.2015.08.003. View

20.

Rachagani S, Macha M, Ponnusamy M, Haridas D, Kaur S, Jain M . MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis. 2012; 33(10):1953-64. PMC: 3529557. DOI: 10.1093/carcin/bgs225. View